Literature DB >> 26659452

Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.

Christophe Cassinotto1,2, Jérome Boursier3,4, Victor de Lédinghen2,5, Jérome Lebigot4,6, Bruno Lapuyade1, Paul Cales3,4, Jean-Baptiste Hiriart5, Sophie Michalak4,7, Brigitte Le Bail2,8, Victoire Cartier4,6, Amaury Mouries1, Frédéric Oberti3,4, Isabelle Fouchard-Hubert3, Julien Vergniol5, Christophe Aubé4,6.   

Abstract

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) has become a major public health issue. The goal of this study was to assess the clinical use of liver stiffness measurement (LSM) evaluated by supersonic shear imaging (SSI), FibroScan, and acoustic radiation force impulse (ARFI) in a cohort of NAFLD patients who underwent liver biopsy. A total of 291 NAFLD patients were prospectively enrolled from November 2011 to February 2015 at 2 French university hospitals. LSM was assessed by SSI, FibroScan (M probe), and ARFI within two weeks prior to liver biopsy. Calculations of the area under the receiver operating curve (AUROC) were performed and compared for the staging of liver fibrosis. AUROC for SSI, FibroScan, and ARFI were 0.86, 0.82, and 0.77 for diagnoses of ≥F2; 0.89, 0.86, and 0.84 for ≥F3; and 0.88, 0.87, and 0.84 for F4, respectively. SSI had a higher accuracy than ARFI for diagnoses of significant fibrosis (≥F2) (P = 0.004). Clinical factors related to obesity such as body mass index ≥ 30 kg/m(2) , waist circumference ≥102 cm or increased parietal wall thickness were associated with LSM failures when using SSI or FibroScan and with unreliable results when using ARFI. In univariate analysis, FibroScan values were slightly correlated with NAFLD activity score and steatosis (R = 0.28 and 0.22, respectively), whereas SSI and ARFI were not; however, these components of NAFLD did not affect LSM results in multivariate analysis. The cutoff values for SSI and FibroScan for staging fibrosis with a sensitivity ≥90% were very close: 6.3/6.2 kPa for ≥F2, 8.3/8.2 kPa for ≥F3, and 10.5/9.5 kPa for F4.
CONCLUSION: Although obesity is associated with an increase in LSM failure, the studied techniques and especially SSI provide high value for the diagnosis of liver fibrosis in NAFLD patients. (Hepatology 2016;63:1817-1827).
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 26659452     DOI: 10.1002/hep.28394

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  116 in total

Review 1.  Non-alcoholic fatty liver disease.

Authors:  James Maurice; Pinelopi Manousou
Journal:  Clin Med (Lond)       Date:  2018-06       Impact factor: 2.659

Review 2.  Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.

Authors:  Jiulian Gu; Shousheng Liu; Shuixian Du; Qing Zhang; Jianhan Xiao; Quanjiang Dong; Yongning Xin
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

Review 3.  Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions.

Authors:  Rohit Loomba
Journal:  J Hepatol       Date:  2017-12-02       Impact factor: 25.083

Review 4.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

5.  Application of point shear wave elastography in alcohol-related liver disease.

Authors:  Vincent Wai-Sun Wong
Journal:  Hepatol Int       Date:  2020-03-06       Impact factor: 6.047

6.  Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease.

Authors:  Hirohito Takeuchi; Katsutoshi Sugimoto; Hisashi Oshiro; Kunio Iwatsuka; Shin Kono; Yu Yoshimasu; Yoshitaka Kasai; Yoshihiro Furuichi; Kentaro Sakamaki; Takao Itoi
Journal:  J Med Ultrason (2001)       Date:  2017-11-11       Impact factor: 1.314

7.  Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience.

Authors:  Mitali M Rath; Manas K Panigrahi; Kaumudee Pattnaik; Pallavi Bhuyan; Sanjib K Kar; Bijay Misra; Debasis Misra; Chudamani Meher; Omprakash Agrawal; Jayshree Rath; Shivaram P Singh
Journal:  J Clin Exp Hepatol       Date:  2016-08-28

Review 8.  Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ma Ai Thanda Han; Rola Saouaf; Walid Ayoub; Tsuyoshi Todo; Edward Mena; Mazen Noureddin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-03-09       Impact factor: 5.045

Review 9.  CON: This Patient Should Have a Noninvasive Assessment of Liver Staging.

Authors:  Rohit Nathan; Deepanshu Jain; Simona Rossi
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-10-09

Review 10.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.